Securities Code: 301393
Securities Abbreviation: Haofan Bio-Pharmaceutical
Announcement Number: 2026-028
Suzhou Haofan Bio-Pharmaceutical Co., Ltd.
Announcement Regarding Receipt of Lawsuit by Hangzhou Foster Pharmaceutical Co., Ltd.
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and there are no false records, misleading statements, or significant omissions.
Key Information Prompt:
-
Stage of the lawsuit: Public prosecution stage
-
Status of the Company's controlling subsidiary: Defendant
-
Impact on the listed company's profit and loss: This lawsuit has not yet been tried, and the outcome is uncertain. The final impact will be subject to the court's judgment.
-
The unit crime matter suspected of Hangzhou Foster was decided and implemented by its former management team before the Company acquired Hangzhou Foster. The Company will actively take relevant legal measures to protect the interests of the Company and its shareholders.
Suzhou Haofan Bio-Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company" or "Haofan Bio-Pharmaceutical") acquired a controlling interest of 85% in Hangzhou Foster Pharmaceutical Co., Ltd. (hereinafter referred to as "Hangzhou Foster," "the Defendant Unit," or "the Target Company") in July 2025. Recently, Hangzhou Foster received a "Indictment" (Qu Long Jian Xing Su [2026] No. 211) from the People's Procuratorate of Longyou County, Zhejiang Province. The relevant situation is hereby announced as follows:
I. Basic情况 of the Lawsuit Case